Risk of Diabetes Treated in Early Adulthood After Growth Hormone Treatment of Short Stature in Childhood.
Growth hormone (GH) is known to be diabetogenic, but the risk of diabetes in individuals treated with GH in childhood has been little evaluated, and conflicting results have been obtained.



To investigate the prevalence of diabetes and gestational diabetes in a population-based cohort of patients treated with GH for short stature in childhood in France.



Participants were a population-based cohort of 5100 children with idiopathic isolated GH deficiency, idiopathic short stature, or short stature in children born short for gestational age who started GH treatment between 1985 and 1996. Data on the delivery of diabetes drugs in 2009 and 2010 were obtained from the French national health insurance database. Cases in patients and controls were identified from diabetes drugs deliveries.



The prevalence of diabetes was calculated and compared with that in the general population, determined on the basis of data from the same source, with the same definition.



At a mean age of 30 years, no difference in the prevalence of treated diabetes (oral drugs or insulin) was found between subjects treated with GH and the general population in France, regardless of sex. Similarly, the risk of insulin-treated gestational diabetes was similar in patients and in the reference population.



No difference in the risk of diabetes was found between GH-treated patients and the reference population. These results are reassuring, but further studies with a longer follow-up are required to evaluate the risk of diabetes with age in these patients.
Université Paris Diderot, Sorbonne Paris Cité, Paris 75019, France.|Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Robert-Debré, Department of Pediatric Endocrinology and Diabetology, and Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Paris 75019, France.|Neuroprotection du cerveau en développement, INSERM, Unversité Paris Diderot, Sorbonne Paris Cité, Paris 75019, France.|Hôtel Dieu, Assistance Publique-Hôpitaux de Paris, Biostatistics and Epidemiology Unit, and APEMAC Equipe d'Accueil 4360, Paris 75004, France.
Amélie
A
Poidvin
Department of Studies in Public Health, French National Health Insurance, Paris 75986, France.
Alain
A
Weill
Hôtel Dieu, Assistance Publique-Hôpitaux de Paris, Biostatistics and Epidemiology Unit, and APEMAC Equipe d'Accueil 4360, Paris 75004, France.
Emmanuel
E
Ecosse
Hôtel Dieu, Assistance Publique-Hôpitaux de Paris, Biostatistics and Epidemiology Unit, and APEMAC Equipe d'Accueil 4360, Paris 75004, France.
Joel
J
Coste
Université Paris Diderot, Sorbonne Paris Cité, Paris 75019, France.|Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Robert-Debré, Department of Pediatric Endocrinology and Diabetology, and Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Paris 75019, France.|Neuroprotection du cerveau en développement, INSERM, Unversité Paris Diderot, Sorbonne Paris Cité, Paris 75019, France.
Jean-Claude
JC
Carel
D000328:Adult; D017668:Age of Onset; D001827:Body Height; D002648:Child; D002675:Child, Preschool; D003920:Diabetes Mellitus / Q000453:epidemiology*; D016640:Diabetes, Gestational / Q000453:epidemiology*; D005260:Female; D005602:France / Q000453:epidemiology; D006130:Growth Disorders / Q000188:drug therapy* / Q000453:epidemiology*; D020249:Hormone Replacement Therapy / Q000009:adverse effects / Q000706:statistics & numerical data; D019382:Human Growth Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age / Q000254:growth & development; D008297:Male; D011247:Pregnancy; D015995:Prevalence; D012307:Risk Factors
D019382:Human Growth Hormone